|Bid||0.9751 x 2200|
|Ask||1.0100 x 1200|
|Day's Range||0.9511 - 1.0100|
|52 Week Range||0.6020 - 3.8100|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2023 - Mar 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.40|
Subscribe to Yahoo Finance Plus to view Fair Value for SURF
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Days conference in New York City on Thursday, February 9, 2023, at 1:35 p.m. ET. A live audio webcast of the session may be accessed by visiting the Events page
Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders should be happy to see the share price up 25% in the last month...
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.